Cargando…

A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis

BACKGROUND: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cup...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianan, Liu, Jixuan, Li, Jixian, Feng, Alei, Nie, Yuanliu, Yang, Zhe, Zhang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465684/
https://www.ncbi.nlm.nih.gov/pubmed/37405477
http://dx.doi.org/10.1007/s00432-023-05005-5
_version_ 1785098726910459904
author Li, Jianan
Liu, Jixuan
Li, Jixian
Feng, Alei
Nie, Yuanliu
Yang, Zhe
Zhang, Wentao
author_facet Li, Jianan
Liu, Jixuan
Li, Jixian
Feng, Alei
Nie, Yuanliu
Yang, Zhe
Zhang, Wentao
author_sort Li, Jianan
collection PubMed
description BACKGROUND: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a novel clinical and therapeutic predictor in esophageal squamous cell carcinoma (ESCC) remains unknown. METHODS: We collected ESCC patient data from the Gene Expression Omnibus and the Cancer Genome Atlas databases and used Gene Set Variation Analysis to score each sample based on cuproptosis and ferroptosis. We then performed weighted gene co-expression network analysis to identify cuproptosis and ferroptosis-related genes (CFRGs) and construct a ferroptosis and cuproptosis-related risk prognostic model, which we validated using a test group. We also investigated the relationship between the risk score and other molecular features, such as signaling pathways, immune infiltration, and mutation status. RESULTS: Four CFRGs (MIDN, C15orf65, COMTD1 and RAP2B) were identified to construct our risk prognostic model. Patients were classified into low- and high-risk groups based on our risk prognostic model and the low-risk group showed significantly higher survival possibilities (P < 0.001). We used the “GO”, “cibersort” and “ESTIMATE” methods to the above-mentioned genes to estimate the relationship among the risk score, correlated pathways, immune infiltration, and tumor purity. CONCLUSION: We constructed a prognostic model using four CFRGs and demonstrated its potential clinical and therapeutic guidance value for ESCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-05005-5.
format Online
Article
Text
id pubmed-10465684
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-104656842023-08-31 A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis Li, Jianan Liu, Jixuan Li, Jixian Feng, Alei Nie, Yuanliu Yang, Zhe Zhang, Wentao J Cancer Res Clin Oncol Research BACKGROUND: Cuproptosis, a form of copper-dependent programmed cell death recently presented by Tsvetkov et al., have been identified as a potential therapeutic target for refractory cancers and ferroptosis, a well-known form describing iron-dependent cell death. However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a novel clinical and therapeutic predictor in esophageal squamous cell carcinoma (ESCC) remains unknown. METHODS: We collected ESCC patient data from the Gene Expression Omnibus and the Cancer Genome Atlas databases and used Gene Set Variation Analysis to score each sample based on cuproptosis and ferroptosis. We then performed weighted gene co-expression network analysis to identify cuproptosis and ferroptosis-related genes (CFRGs) and construct a ferroptosis and cuproptosis-related risk prognostic model, which we validated using a test group. We also investigated the relationship between the risk score and other molecular features, such as signaling pathways, immune infiltration, and mutation status. RESULTS: Four CFRGs (MIDN, C15orf65, COMTD1 and RAP2B) were identified to construct our risk prognostic model. Patients were classified into low- and high-risk groups based on our risk prognostic model and the low-risk group showed significantly higher survival possibilities (P < 0.001). We used the “GO”, “cibersort” and “ESTIMATE” methods to the above-mentioned genes to estimate the relationship among the risk score, correlated pathways, immune infiltration, and tumor purity. CONCLUSION: We constructed a prognostic model using four CFRGs and demonstrated its potential clinical and therapeutic guidance value for ESCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-023-05005-5. Springer Berlin Heidelberg 2023-07-05 2023 /pmc/articles/PMC10465684/ /pubmed/37405477 http://dx.doi.org/10.1007/s00432-023-05005-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Li, Jianan
Liu, Jixuan
Li, Jixian
Feng, Alei
Nie, Yuanliu
Yang, Zhe
Zhang, Wentao
A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
title A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
title_full A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
title_fullStr A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
title_full_unstemmed A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
title_short A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
title_sort risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465684/
https://www.ncbi.nlm.nih.gov/pubmed/37405477
http://dx.doi.org/10.1007/s00432-023-05005-5
work_keys_str_mv AT lijianan ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT liujixuan ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT lijixian ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT fengalei ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT nieyuanliu ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT yangzhe ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT zhangwentao ariskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT lijianan riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT liujixuan riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT lijixian riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT fengalei riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT nieyuanliu riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT yangzhe riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis
AT zhangwentao riskprognosticmodelforpatientswithesophagealsquamouscellcarcinomabasingoncuproptosisandferroptosis